MEK/MAPK Inhibitors  by Dy, Grace
MEK/MAPK Inhibitors
Grace Dy
An overview of the rationale and the clinical developmentof various agents that inhibit the MEK/mitogen-activated
protein kinase, pathway were presented by Drs. Mien Chie
Hung, Grace Dy, Pasi Janne, Ross Camidge, and Jeffrey
Engelman. The canonical proliferative RAS-RAF-MEK-
ERK pathway is one of the major deregulated signaling
pathways implicated in various malignancies. Ras is consti-
tutively activated by mutations that occur in approximately
30% of non-small cell lung cancer (NSCLC). Activating
B-raf mutations, which commonly occur in melanoma and
thyroid cancers (70%), can also be seen in a small group of
NSCLC (5%). Multiple agents have been developed over
the years ostensibly against ras, but efforts have foundered
clinically, and it has remained an elusive “undruggable”
target to this date. MEK is a rationale target for drug devel-
opment as it is an important downstream mediator, not only
of Ras activation but also of other oncogenic signaling
pathways as well such as the phosphatidylinositol 3-kinase
(PI3K)-mammalian target of rapamycin (mTOR) pathway.
AZD6244 (Selumetinib) is a selective, ATP-uncom-
petitive inhibitor of MEK1/2. It locks MEK1/2 into an inac-
tive conformation thereby inhibiting subsequent ERK phos-
phorylation, which, however, is not correlated with the ability
to achieve tumor growth inhibition. In a screen of a panel of
cell lines exposed to AZD6244, the majority of sensitive cell
lines (IC50  1 mol/liter) harbor mutations in B-raf or Ras
(e.g., N-ras or K-ras), whereas wild-type cell lines were
typically resistant (IC50  10 mol/liter). K-ras mutant cell
lines exhibit greater variability in sensitivity. Preclinical in-
vestigations also reveal synergistic effect on the growth of
mutant Kras xenografts of AZD6244 in combination with
various chemotherapy agents such as docetaxel or irinote-
can.1
A number of randomized phase II studies have been
completed. When compared against pemetrexed in a 1:1
randomization scheme as second- or third-line therapy in 84
patients with advanced NSCLC, 70% in AZD6244 group
versus 59% in the pemetrexed group had disease progression
(HR, 1.35, p  0.30) with median PFS of 67 versus 90 days,
respectively (partial response, 1.08, p  0.79).2 In metastatic
melanoma, final results reported showed no significant dif-
ference in PFS and OS between temozolomide and
AZD6244. Prespecified subgroup analyses revealed that pa-
tients whose tumors were B-raf mutants had PFS and OS HR
of 0.85 and 0.68, respectively (80% CI crossing 1.0). Al-
though majority of patients who had partial responses in the
AZD6244 treatment group had B-raf mutant tumors (83% of
responders), this represents merely 11% of all patients in this
treatment arm with B-raf mutant tumors, hence a subsequent
phase III study was not planned.3 In a similar design con-
ducted in patients with advanced colorectal cancer, 82% in
AZD6244 group versus 80% in capecitabine group had dis-
ease progression (HR, 1.08, p  0.8) with median PFS of 81
versus 88 days, respectively (HR 1.08 p  0.78).4 A single-
arm phase II study in patients with advanced hepatocellular
carcinoma was stopped after interim analysis due to lack of
clinical benefit.5 The mediocre results maybe attributable to
dilution of treatment effect in an unselected patient popula-
tion. There is sufficient evidence to suggest that the presence
of certain B-raf or K-ras mutations may be predictive of
sensitivity to treatment with MEK inhibitors.1,6,7 To address
this issue, additional ongoing randomized phase II studies are
specific for K-ras mutant NSCLC (comparing docetaxel ver-
sus docetaxel with AZD6244 as second-line therapy) and
B-raf mutant melanoma (comparing dacarbazine versus
dacarbazine with AZD6244 as first-line therapy in mela-
noma).
RDEA-119 is another oral, highly selective allosteric
inhibitor of MEK 1/2 that inhibits MEK 1/2 in vitro with an
IC50 17 to 50 nM; in a screen panel of a variety of cancer cell
lines, RDEA-119 is able to inhibit ERK phosphorylation at an
EC50 of 2.5 to 15.8 nM. V600E Braf mutant-xenograft mod-
els demonstrate exquisite schedule-dependent growth inhibi-
tion on exposure to RDEA-119. Twice-daily dosing schedule
was found to be more effective than a once-daily schedule,
which correlated with achieving a threshold trough concen-
tration level (versus Cmax). Compared with other MEK
inhibitors, RDEA-119 had relatively lower central nervous
penetration.8 Combination studies suggest that RDEA119 and
sorafenib synergistically inhibit proliferation in a variety of
cancer cell lines both in vitro and in vivo.9 Phase I study of
RDEA 119 as a single agent10 and in combination with
sorafenib is ongoing.
Other MEK inhibitors in early clinical development
include AZD8330, GDC-0973/XL-518, AS703026,
GSK1120212, and RO5126766. Toxicities that are likely
mechanism based and seen in various agents of this class
include acneiform dermatitis, diarrhea, nausea, vomiting,
fatigue, peripheral edema, reversible visual disturbances
(abnormal color perception, blurred vision, and visual field
defect due to retinal vein occlusion or retinopathy), and
other central nervous system effects (e.g., hallucinations
and confusion).
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Several factors may be implicated in the mechanism of
resistance to MEK inhibition. FOXO3a, a transcription factor
in the FOXO family, is a tumor suppressor, which is down-
regulated by ERK activation. It has been shown that suppres-
sion of FOXO3a function, which maybe manifested as in-
ability to undergo nuclear translocation, may contribute to
resistance to MEK inhibition. Conversely, relocalization of
FOXO3a to the nucleus may restore treatment sensitivity. It
is, thus, hypothesized that cytoplasmic FOXO3a localization
may serve as a marker for predicting resistance to MEK
inhibitors and that restoring FOXO3a function may confer
sensitivity.11 Signaling pathways exhibit network properties,
such that feedback loops, transactivation, and cross-regula-
tion occur within and between various signal transduction
pathways. The need for combinatorial approaches to maxi-
mize therapeutic efficacy of and overcome resistance to MEK
inhibitors in NSCLC is well recognized. Indeed, activation
status of PI3K/Akt signaling has been demonstrated to deter-
mine susceptibility of cancer cells to MEK inhibition, e.g.,
presence of phosphorylated Akt predicts for treatment resis-
tance to MEK inhibitors.12 The heterogeneity of response to
MEK inhibitors among K-ras mutants is likely attributable to
the presence of other comutations.7,13 Indeed synergistic
antitumor effect is demonstrated with the combination of
PI3K and MEK inhibitors in the treatment of K-ras mutated
lung cancer murine model.13 Conversely, MEK inhibitors
augment the antitumor response to mTOR inhibition as the
latter triggers a PI3K-dependent feedback loop that activates
the mitogen-activated protein kinase, pathway.14 These pro-
vide the rationale for studies evaluating the combination of
MEK inhibitors with agents that modulate the PI3K-mTOR-
Akt pathway. Of note is the phase I study combining
AZD6244 and MK2206, an oral Akt inhibitor, which repre-
sents the long-awaited collaboration between two pharmaceu-
tical companies at an early stage of drug development and
hopefully presages a paradigmatic shift in the clinical evalu-
ation of anticancer therapies.
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